These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 35396315)

  • 1. Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial.
    Ogasawara S; Koroki K; Makishima H; Wakatsuki M; Takahashi A; Yumita S; Nakagawa M; Ishino T; Ogawa K; Fujiwara K; Iwanaga T; Sakuma T; Fujita N; Kojima R; Kanzaki H; Kobayashi K; Kiyono S; Nakamura M; Kanogawa N; Saito T; Kondo T; Nakagawa R; Nakamoto S; Muroyama R; Chiba T; Ozawa Y; Kawasaki Y; Kurokawa T; Hanaoka H; Tsuji H; Kato N
    BMJ Open; 2022 Apr; 12(4):e059779. PubMed ID: 35396315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
    Antonia S; Goldberg SB; Balmanoukian A; Chaft JE; Sanborn RE; Gupta A; Narwal R; Steele K; Gu Y; Karakunnel JJ; Rizvi NA
    Lancet Oncol; 2016 Mar; 17(3):299-308. PubMed ID: 26858122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
    Powles T; van der Heijden MS; Castellano D; Galsky MD; Loriot Y; Petrylak DP; Ogawa O; Park SH; Lee JL; De Giorgi U; Bögemann M; Bamias A; Eigl BJ; Gurney H; Mukherjee SD; Fradet Y; Skoneczna I; Tsiatas M; Novikov A; Suárez C; Fay AP; Duran I; Necchi A; Wildsmith S; He P; Angra N; Gupta AK; Levin W; Bellmunt J;
    Lancet Oncol; 2020 Dec; 21(12):1574-1588. PubMed ID: 32971005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma.
    Fujiwara Y; Takahashi Y; Okada M; Kishimoto T; Kondo S; Fujikawa K; Hayama M; Sugeno M; Ueda S; Komuro K; Lanasa M; Nakano T
    Oncologist; 2022 Sep; 27(9):e703-e722. PubMed ID: 35671201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma.
    Patel TH; Brewer JR; Fan J; Cheng J; Shen YL; Xiang Y; Zhao H; Lemery SJ; Pazdur R; Kluetz PG; Fashoyin-Aje LA
    Clin Cancer Res; 2024 Jan; 30(2):269-273. PubMed ID: 37676259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
    Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
    Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.
    Kelley RK; Sangro B; Harris W; Ikeda M; Okusaka T; Kang YK; Qin S; Tai DW; Lim HY; Yau T; Yong WP; Cheng AL; Gasbarrini A; Damian S; Bruix J; Borad M; Bendell J; Kim TY; Standifer N; He P; Makowsky M; Negro A; Kudo M; Abou-Alfa GK
    J Clin Oncol; 2021 Sep; 39(27):2991-3001. PubMed ID: 34292792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.
    Abou-Alfa GK; Lau G; Kudo M; Chan SL; Kelley RK; Furuse J; Sukeepaisarnjaroen W; Kang YK; Van Dao T; De Toni EN; Rimassa L; Breder V; Vasilyev A; Heurgué A; Tam VC; Mody K; Thungappa SC; Ostapenko Y; Yau T; Azevedo S; Varela M; Cheng AL; Qin S; Galle PR; Ali S; Marcovitz M; Makowsky M; He P; Kurland JF; Negro A; Sangro B
    NEJM Evid; 2022 Aug; 1(8):EVIDoa2100070. PubMed ID: 38319892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase Ib study of durvalumab (MEDI4736) in combination with carbon-ion radiotherapy and weekly cisplatin for patients with locally advanced cervical cancer (DECISION study): study protocol for a prospective open-label single-arm study.
    Okonogi N; Usui H; Murata K; Hori M; Kurokawa T; Fujiwara T; Fujii Y; Hanawa M; Kawasaki Y; Hattori Y; Suzuki K; Tsuyuki K; Wakatsuki M; Hasegawa S; Yamada S; Hanaoka H; Shozu M; Tsuji H
    BMJ Open; 2022 Mar; 12(3):e056424. PubMed ID: 35236732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial.
    Boilève A; Hilmi M; Gougis P; Cohen R; Rousseau B; Blanc JF; Ben Abdelghani M; Castanié H; Dahan L; Tougeron D; Metges JP; Tournigand C; Garcia-Larnicol ML; Vernerey D; Turpin A; Neuzillet C
    Eur J Cancer; 2021 Jan; 143():55-63. PubMed ID: 33279854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ).
    Bang YJ; Golan T; Dahan L; Fu S; Moreno V; Park K; Geva R; De Braud F; Wainberg ZA; Reck M; Goff L; Laing N; Mi G; Oliveira JM; Wasserstrom H; Lin CC
    Eur J Cancer; 2020 Sep; 137():272-284. PubMed ID: 32827847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
    Rizvi NA; Cho BC; Reinmuth N; Lee KH; Luft A; Ahn MJ; van den Heuvel MM; Cobo M; Vicente D; Smolin A; Moiseyenko V; Antonia SJ; Le Moulec S; Robinet G; Natale R; Schneider J; Shepherd FA; Geater SL; Garon EB; Kim ES; Goldberg SB; Nakagawa K; Raja R; Higgs BW; Boothman AM; Zhao L; Scheuring U; Stockman PK; Chand VK; Peters S;
    JAMA Oncol; 2020 May; 6(5):661-674. PubMed ID: 32271377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma.
    Bahig H; Aubin F; Stagg J; Gologan O; Ballivy O; Bissada E; Nguyen-Tan FP; Soulières D; Guertin L; Filion E; Christopoulos A; Lambert L; Tehfe M; Ayad T; Charpentier D; Jamal R; Wong P
    BMC Cancer; 2019 Jan; 19(1):68. PubMed ID: 30642290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of radiotherapy combined with atezolizumab plus bevacizumab in treating hepatocellular carcinoma with portal vein tumour thrombus: a study protocol.
    Wang K; Yu HM; Xiang YJ; Cheng YQ; Ni QZ; Guo WX; Shi J; Feng S; Zhai J; Cheng SQ
    BMJ Open; 2022 Dec; 12(12):e064688. PubMed ID: 36521893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.
    Kelly RJ; Lee J; Bang YJ; Almhanna K; Blum-Murphy M; Catenacci DVT; Chung HC; Wainberg ZA; Gibson MK; Lee KW; Bendell JC; Denlinger CS; Chee CE; Omori T; Leidner R; Lenz HJ; Chao Y; Rebelatto MC; Brohawn PZ; He P; McDevitt J; Sheth S; Englert JM; Ku GY
    Clin Cancer Res; 2020 Feb; 26(4):846-854. PubMed ID: 31676670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment.
    Sho T; Suda G; Ohara M; Kohya R; Sasaki T; Yoshida S; Hosoda S; Ogawa K; Kitagataya T; Maehara O; Ohnishi S; Kawagishi N; Natsuizaka M; Nakai M; Baba M; Yamamoto Y; Tsukuda Y; Meguro T; Yamada R; Kobayashi T; Takagi T; Sakamoto N;
    Target Oncol; 2024 Sep; 19(5):769-778. PubMed ID: 39222223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies.
    Nehra J; Bradbury PA; Ellis PM; Laskin J; Kollmannsberger C; Hao D; Juergens RA; Goss G; Wheatley-Price P; Hotte SJ; Gelmon K; Tinker AV; Brown-Walker P; Gauthier I; Tu D; Song X; Khan A; Seymour L; Smoragiewicz M
    Invest New Drugs; 2020 Oct; 38(5):1442-1447. PubMed ID: 32020438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma.
    France NL; Blair HA
    Target Oncol; 2024 Jan; 19(1):115-123. PubMed ID: 38236364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
    Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
    Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.
    Falchook GS; Peeters M; Rottey S; Dirix LY; Obermannova R; Cohen JE; Perets R; Frommer RS; Bauer TM; Wang JS; Carvajal RD; Sabari J; Chapman S; Zhang W; Calderon B; Peterson DA
    Invest New Drugs; 2021 Oct; 39(5):1284-1297. PubMed ID: 33852104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.